MedPharm receives new patents for MedSpray topical spray-on-film technology

MedPharm receives new patents for MedSpray topical spray-on-film technology

MedSpray® is a novel transdermal and topical drug delivery tool that can be used to deliver drugs in extended release form via spray-on-films delivered to the skin or other mucosal (topical) membranes. MedSpray® offers many advantages over traditional drug delivery systems. The technology allows enhanced drug delivery into or across the skin/mucosal membranes by creating a film, which can be manipulated to suit the specific drug and disease. This results in a lack of first pass metabolism, improved toxicity profiles and the potential for sustained and targeted drug delivery To date, MedSpray® has been trialled with over 20 drugs up to and including clinical evaluation.

CEO Dr Andrew Muddle commented: "We now have patents for MedSpray® in key countries throughout Europe, North America, and the rest of the world including, Brazil, Russia, India and China. Widening our patent coverage will enable us to bolster the commercial use of the technology. Currently MedPharm has a number of licensees developing products with this technology and with these new patents, the company can continue to expand licenced products into new markets."

"Our strategy is to work successfully with partners to develop new products with drugs provided by licensees," continues Dr Muddle. "All such MedSpray® agreements are based upon payment of royalties and contract development fees to MedPharm."

SOURCE MedPharm Ltd

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.